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Nerve Growth Factor (NGF) is a neurotrophin that regulates the
structure and function of responsive sensory neurons and is a
regulator of pain sensitivity and processing1. The concept of tar-
geting NGF to target chronic pain syndromes has been gaining
momentum since 19902. To date, there have been 44 clinical trials
registered/listed on www.clinicaltrials.gov (last accessed June 10,
2014) with anti-NGF (aNGF) monoclonal antibodies (mAbs): 42
were conducted with two studies “Withdrawn” prior to subject
enrollment (see Table I).
On June 22 2010, the American Food and Drug Association (FDA)
put the Tanezumab osteoarthritis (OA)3,4 program on hold due to
an increased number of adverse events (AEs), namely osteonec-
rosis, as reported by the investigators, which lead to joint
replacement. Subsequently all clinical trial programs were put on
hold by the FDA on December 23 2010 for all indications except
cancer pain. On March 12 2012, the FDA Arthritis Advisory Com-
mittee reviewed all the results and strongly endorsed that there* Address correspondence and reprint requests to: C.G. Miller, Medical Affairs
BioClinica, Inc. 826 Newtown e Yardley Road, Newtown, PA 18940, USA. Tel: 1-267-
757-3144.
E-mail address: colin.miller@bioclinica.com (C.G. Miller).
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1063-4584/© 2014 Osteoarthritis Research Society International. Published by Elsevier Lshould be continued clinical development of the aNGF's5, with
caveats to screen out those subjects with a preexisting subchondral
insufﬁciency fracture (SIF) and osteonecrosis or those at risk of
developing these conditions.
The use of medical imaging to evaluate the eligibility and safety
has therefore taken on a major importance. To fulﬁll the FDA re-
quirements for restarting the programs5, radiological evaluation of
all major articulating joints will have to be conducted.
Review of aNGF trials
A thorough review was performed on the web site www.
clinicaltrials.gov to identify all aNGF studies that have been con-
ducted up to May 31 2014. The terms aNGF, and aNGF only returned
a limited number of results so the individual compounds had to be
identiﬁed either by generic name or compound number. 44 studies
were identiﬁed and although two had been withdrawn prior to
randomization, a total of 15,664 subjects have been enrolled in
studies with the aNGF mAbs. Seven of these trials have been pub-
lished in peer review journals3,4,6e10. Table I lists all studies, con-
ditions and related publications. While the majority (26) of studies
have been conducted by Pﬁzer with Tanezumab (one listed as aNGF
AB), there havebeen sevenwith Fulranumabprevious known as JNJ-
42160443 (Johnson & Johnson Pharmaceutical Research & Devel-
opment), and nine with Fasinumab previously known as REGN475
(Regeneron pharmaceuticals/Sanoﬁ). Many of the studies have been
either terminated (24), or completed (16) but there is one currently
active (not recruiting) in cancer-related pain (Fulranumab).
The number of indications that have been studied comprise of
OA (21), which includes either the knee, hip or both; low back pain
(4), and a variety of pain syndromes (11) including neuropathic pain
fromdiabetes (2), plus three in cancer pain ofwhich one is on-going.
Clinical trials evaluating pain as a primary outcome generally do
not require radiological assessments. However, imaging was prob-
ably used for the majority of studies in OA during subject screening
for the classiﬁcation of disease state, but not for anything further.
Safety issues seen in aNGF clinical trials
In the Tanezumab program 249 subjects were adjudicated for
AEs related to the joints. Of these 68 had Rapidly Progressing OAtd. All rights reserved.
Table I
A listing of all clinical trials evaluating aNGF compounds up until June 10 2014. NB: Under the heading “Interventions”, the number in superscript refers to the sponsoring
company: 1) PG110 sponsored by Abbott (now Abbvie); 2) MEDI-578 sponsored by AstraZeneca/Medimmune LLC; 3) Fulranumab sponsored by Johnson & Johnson (now
Janssen Pharmaceuticals); 4) Tanezumab sponsored by Pﬁzer; 5) Fasinumab sponsored by Regeneron Pharmaceuticals/Sanoﬁ. NCT ¼ National Clinical Trial and the number is
the unique identiﬁer at the site www.clinicaltrials.gov
# NCT number Title Status Conditions Interventions # of
subjects
Publications
1 NCT00941746 Safety and Tolerability of
PG110 in Patients With
Knee Osteoarthritis Pain
Completed Osteoarthritis, Knee PG1101 56
2 NCT01072591 Study to Assess MEDI-578
in Patients With
Osteoarthritis (OA) of the
Knee
Terminated OsteoarthritisjPain MEDI-5782 108
3 NCT00929188 A Study of the Safety and
Effectiveness of JNJ-
42160443 as add-on
Treatment in Patients With
Cancer-related Pain
Active,
not recruiting
Pain, BurningjPain, CrushingjPain, MigratoryjPain,
RadiatingjPain, Splitting
Fulranumab3 100
4 NCT00993018 A Study of Effectiveness and
Safety of JNJ-42160443 in
Patients With Diabetic
Painful Neuropathy
Terminated Diabetic Neuropathy Fulranumab3 77
5 NCT00973141 A Dose-ranging Study of the
Safety and Effectiveness of
JNJ-42160443 as add-on
Treatment in Patients With
Osteoarthritis-related Pain
Terminated OsteoarthritisjOsteoarthritis, HipjOsteoarthritis,
KneejPainjArthralgiajJoint Pain
Fulranumab3 467
6 NCT00973024 A Dose-ranging Study of the
Safety and Effectiveness of
JNJ-42160443 as add-on
Treatment in Patients With
Low Back Pain
Terminated Low Back PainjLow Back Pain, Recurrent Fulranumab3 389
7 NCT01094262 A Safety and Tolerability
Study of JNJ-42160443 in
Patients With Moderate to
Severe, Chronic Knee Pain
From Osteoarthritis
Terminated OsteoarthritisjOsteoarthritis,
KneejPainjArthralgiajJoint Pain
Fulranumab3 196
8 NCT01060254 A Study to Evaluate the Pain
Relieving Effects, Safety,
and Tolerability of JNJ-
42160443 for the Relief of
Bladder Pain
Terminated Cystitis, InterstitialjUrologic DiseasesjUrinary
Bladder DiseasesjCystitis
Fulranumab3 31
9 NCT00964990 A Study to Evaluate the
Efﬁcacy, Safety, and
Tolerability of JNJ-
42160443 in Patients With
Neuropathic Pain
(Postherpetic Neuralgia and
Post-traumatic Neuralgia)
Terminated PainjNeuralgia, PostherpeticjNeuralgiaj
Mononeuropathies
Fulranumab3 112
10 NCT00809354 Long-Term Analgesic
Efﬁcacy And Safety Of
Tanezumab Alone Or In
Combination With Non-
Steroidal Anti-
Inﬂammatory Drugs
(NSAIDs) Versus NSAIDs
Alone In Patients With
Osteoarthritis Of The Knee
Or Hip
Terminated OsteoarthritisjArthritis Tanezumab4 2720 9
11 NCT00864097 Analgesic Efﬁcacy And
Safety of Tanezumab Added
On To Diclofenac SR In
PatientsWith Osteoarthritis
Of The Knee Or Hip
Terminated Osteoarthritis Tanezumab4 607 6
12 NCT00876187 A Study of Tanezumab in
Adults With Chronic Low
Back Pain
Completed Low Back Pain Tanezumab4 1359
13 NCT01089725 Efﬁcacy And Safety Study Of
Tanezumab Subcutaneous
Administration In
Osteoarthritis - A
Subcutaneous/Intravenous
Bridging Study
Terminated OsteoarthritisjArthritisjPain Tanezumab4 385
14 NCT01030640 Study To Assess Changes In
The Number Of Nerves In
The Skin At The Site Where
Where Tanezumab Is
Injected
Completed Osteoarthritis PainjChronic Low Back PainjPain
Due to Interstitial Cystitis
Tanezumab4 28
C.G. Miller et al. / Osteoarthritis and Cartilage 23 (2015) S3eS7S4
Table I (continued )
# NCT number Title Status Conditions Interventions # of
subjects
Publications
15 NCT00809783 Extension Study Of
Tanezumab In
Osteoarthritis
Terminated Osteoarthritis Tanezumab4 2147
16 NCT01087203 A Study Of The Analgesic
(Pain-Relief) Effects Of
Tanezumab In Adult
Patients With Diabetic
Peripheral Neuropathy
Terminated Diabetic Peripheral Neuropathy Tanezumab4 73
17 NCT00744471 Tanezumab in
Osteoarthritis Of The Hip
Completed ArthritisjOsteoarthritisjOsteoarthritis, Hip Tanezumab4 627 4
18 NCT00924664 Long Term Safety Study of
Tanezumab in Chronic Low
Back Pain
Terminated Low Back Pain Tanezumab4 849
19 NCT00863772 Tanezumab and Nerve
Function In Arthritis
Patients
Terminated Osteoarthritis Tanezumab4 220
20 NCT01146561 Safety And Efﬁcacy Of
Tanezumab In Patients
With Chronic Pancreatitis
Terminated Chronic Pancreatitis Tanezumab4 2
21 NCT01127893 Safety Extension Study Of
Tanezumab When
Administered By
Subcutaneous Injection To
PatientsWith Osteoarthritis
Terminated Osteoarthritis Tanezumab4 1
22 NCT00994890 A Long Term Study of the
Safety of Tanezumab When
Administered By
Subcutaneous Injections
Terminated Osteoarthritis, KneejOsteoarthritis, Hip Tanezumab4 679
23 NCT00545129 A Study Of Tanezumab as
Add-On Therapy to Opioid
Medication In PatientsWith
Pain Due To Cancer That
Has Spread To Bone
Completed Neoplasm MetastasisjPalliative Care Tanezumab4 59 7
24 NCT00784693 A Clinical Study To
Investigate The
Effectiveness And Safety Of
Tanezumab In Treating Pain
Associated With
Endometriosis
Terminated Endometriosis Tanezumab4 48
25 NCT00788294 Measure Exposure Of
Tanezumab In Healthy
Volunteers When
Administering The Drug
Subcutaneously
Completed Healthy Volunteers Tanezumab4 76
26 NCT00999518 A Study To Investigate
Tanezumab In Patients
With Interstitial Cystitis/
Painful Bladder Syndrome
Terminated Cystitis, Interstitial Tanezumab4 222
27 NCT00733902 Tanezumab in
Osteoarthritis of the Knee
Completed ArthritisjOsteoarthritis Tanezumab4 697 3
28 NCT00960804 Long-Term Study Of The
Safety Of Tanezumab In
Arthritis Patients
Terminated Osteoarthritis Tanezumab4 21
29 NCT00830063 Tanezumab In Osteoarthritis
Of The Knee (2)
Completed Arthritis/Osteoarthritis Tanezumab4 848
30 NCT00863304 Tanezumab in
Osteoarthritis of the Hip or
Knee (2)
Completed Osteoarthritis Tanezumab4 849
31 NCT00985621 Tanezumab In
Osteoarthritis Of The Hip Or
Knee
Terminated Osteoarthritis Tanezumab4 600
32 NCT00826514 An Efﬁcacy And Safety
Study Of Tanezumab For
The Treatment Of Pain
Associated With Chronic
Abacterial Prostatitis
Completed Chronic Prostatitis With Chronic Pelvic
Pain Syndrome
Tanezumab4 62
33 NCT00830180 Open Label Extension In
Cancer Patients
Completed Neoplasms/Bone Metastases Tabezumab4 41
34 NCT00669409 A Phase 1/2A, Single Dose
Study Of PF-04383119 In
Japanese Patients With
Moderate To Severe Pain
Completed Osteoarthritis, Knee Tanezumab4 83 8
(continued on next page)
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Table I (continued )
# NCT number Title Status Conditions Interventions # of
subjects
Publications
From Osteoarthritis Of The
Knee
35 NCT01362660 A Study to Evaluate Infants
with Potential Exposure to
Tanezumab Before Birth
Completed Infant Development Assessment Tanezumab4 7
36 NCT00856310 A Single-Dose Study of the
Safety and Tolerability of
REGN475(SAR164877) in
Healthy Subjects
Completed Healthy Fasinumab5 56
37 NCT01001715 Single Injection of
REGN475/SAR164877 in
Treatment of Vertebral
Fracture Pain
Terminated Back Pain Fasinumab5 41
38 NCT01001923 Single Injection of
REGN475/SAR164877 in
the Treatment of Chronic
Pancreatitis Pain
Terminated Abdominal Pain Upper Fasinumab5 15
39 NCT01239017 A Study of the Safety and
Efﬁcacy of Subcutaneously
Administered REGN475 in
PatientsWith Osteoarthritis
of the Knee
Withdrawn Osteoarthritis Fasinumab5 250 10
40 NCT00991172 A Study to Evaluate the
Safety and Efﬁcacy of
Subcutaneously
Administered
REGN475(SAR164877) in
Patients With Sciatic Pain
Completed Sciatica Fasinumab5 159
41 NCT00944892 A Study of the Safety and
Efﬁcacy of
REGN475(SAR164877) in
PatientsWith Osteoarthritis
of the Knee
Completed Osteoarthritis of the Knee Fasinumab5 200
42 NCT01053702 Study of the Safety and
Efﬁcacy of
REGN475(SAR164877) in
Patients With Pain
Resulting From Thermal
Injury
Withdrawn Thermal Injury Pain Fasinumab5 0
43 NCT00856310 A Single-Dose Study of the
Safety and Tolerability of
REGN475(SAR164877) in
Healthy Subjects
Completed Healthy Fasinumab5 56
44 NCT01001715 Single Injection of
REGN475/SAR164877 in
Treatment of Vertebral
Fracture Pain
Terminated Back Pain Fasinumab5 41
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for chronic back pain. The advisory board noted that 13 of the 68
subjects had deﬁnite evidence of SIF at enrollment11. This program
had the largest number of enrolled subjects at the time of FDA
cessation of the program (13,310 subjects of the 15,664 enrolled in
aNGF studies or 85%). While these subjects were identiﬁed post hoc,
SIF, RPOA and joint destructionwas not an AE that was anticipated a
priori and therefore nothing pro-actively built into the studies to
evaluate the true incidence of these events. RPOAwas split into two
types: RPOA Type 1 is deﬁned as a signiﬁcant loss of joint space
width (2 mm) within approximately 1 year without gross struc-
tural failure and RPOA Type 2 is deﬁned as abnormal bone loss or
destruction, including limited or total collapse of at least one sub-
chondral surface (such as the medial femoral condyle of the knee)
that is not normally present in conventional end-stage OA (5). No
work was presented on low bone mineral density, a predisposition
for SIF.The role of imaging in future aNGF trials
The prior aNGF studies utilized imaging for diagnosis or prognosis
for eligibility criteria, but not for monitoring the outcome. All the
radiographic safety concerns have come from post hoc review and
analyses, butwerenot structuredapriori. Future studies, as requested
by the FDA5, will require amore thorough evaluation of images of the
major articulating joints, to ensure subjects are not enrolled with
underlying pathologies leading to SIF, RPOA or OA and then moni-
tored for safety signs that might be developing before catastrophic
joint damage occurs. This combination of imaging utilization is un-
usual, but will be highly critical for all future trials.Without thorough
radiological screeningof thesubjects, itwill be impossible toelucidate
whether these AEs are a true drug effect or an underlying issuewhich
is exacerbated, when pain is removed or decreased from the subject.
In summary, medical imaging and the thorough radiological
evaluation of the major articulating joints for all subjects in future
C.G. Miller et al. / Osteoarthritis and Cartilage 23 (2015) S3eS7 S7aNGF studies will be required. The ﬁrst step will be to rule out
possible pathology or those at high risk of going onto a catastrophic
joint failure. Then secondly to closely monitor the subjects during
the treatment phase to ensure that any possible events will be
identiﬁed appropriately and the subject managed to prevent any
further bone or joint damage. This atlas was developed in light of
these issues to provide a common framework and understanding
for all radiologists working in this ﬁeld.
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